Member Posts > Cardiol Therapeutics Advances CRD-38 Toward Clinical Trials Following Landmark Research Publication
Cardiol Therapeutics has taken a major step forward in advancing CRD-38, its subcutaneous cannabidiol-based drug candidate, with the publication of groundbreaking research in the Journal of the American College of Cardiology: Basic to Translational Science.
The study provides key evidence that CRD-38 reduces heart failure progression through mitochondrial preservation and anti-inflammatory mechanisms. These findings are expected to support the company's upcoming IND submission and regulatory engagements as it moves toward clinical development.

#CardiolTherapeutics #BiotechInvesting #ClinicalTrials #PharmaStocks #CBDTherapeutics #HeartHealth #StockMarket #InvestingInBiotech #HealthcareInnovation #OrphanDrug #Myocarditis #Pericarditis #FDAApproval #GrowthStocks #MedicalBreakthroughs #CRD38 #CardiolRx